AR039628A2 - MASSABLE FORMULATION OF CARPROPHENE, IMPLANT AND THERAPEUTIC COMPOSITION - Google Patents
MASSABLE FORMULATION OF CARPROPHENE, IMPLANT AND THERAPEUTIC COMPOSITIONInfo
- Publication number
- AR039628A2 AR039628A2 ARP030101251A ARP030101251A AR039628A2 AR 039628 A2 AR039628 A2 AR 039628A2 AR P030101251 A ARP030101251 A AR P030101251A AR P030101251 A ARP030101251 A AR P030101251A AR 039628 A2 AR039628 A2 AR 039628A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- implant
- formulation
- carprophene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación masticable, un implante y una composición que comprenden carprofeno. Una composición caracterizada porque comprende una cantidad terapéuticamente efectiva de un compuesto de fórmula (1), en la que, R2 es -(CXY)n-C(O)-A, donde A es hidroxi, alcoxi (C1-4), amino, hidroxiamino, mono-alquilamino(C1-2), di-alquilamino(C1-2); X e Y son, independientemente, H o alquilo(C1-2); y n es 1 ó 2; R6 es halógeno, alquilo (C1-3), trifluorometilo o nitro; R9 es H; alquilo(C1-2); fenilo o fenil-alquilo(C1-2), donde el fenilo está opcionalmente mono-sustituido con fluoro o cloro; -C(=O)-R, donde R es alquilo(C1-2) o fenilo, opcionalmente mono-sustituido con fluoro o cloro; o -C(=O)-O-R1, donde R1 es alquilo(C1-2); donde X e Y son diferentes, los enantiómeros (-)(R) y (+)(S) de los mismos; y todas las formas de sales farmacéuticamente aceptables, profármacos y metabolitos de los mismos, en una forma de dosificación controlada que sea capaz de mantener los niveles de plasma por sobre aproximadamente 10 micro g/ml durante un período mayor a 10,5 horas. Estos son útiles en el tratamiento del dolor y de la inflamación con una menor incidencia de efectos secundarios.A chewable formulation, an implant and a composition comprising carprofen. A composition characterized in that it comprises a therapeutically effective amount of a compound of formula (1), wherein, R2 is - (CXY) nC (O) -A, where A is hydroxy, (C1-4) alkoxy, amino, hydroxyamino , mono-C1-2 alkylamino, di-C1-2 alkylamino; X and Y are, independently, H or (C1-2) alkyl; and n is 1 or 2; R6 is halogen, (C1-3) alkyl, trifluoromethyl or nitro; R9 is H; (C1-2) alkyl; phenyl or phenyl (C1-2) alkyl, where the phenyl is optionally mono-substituted with fluoro or chloro; -C (= O) -R, where R is (C1-2) alkyl or phenyl, optionally mono-substituted with fluoro or chloro; or -C (= O) -O-R1, where R1 is (C1-2) alkyl; where X and Y are different, the (-) (R) and (+) (S) enantiomers thereof; and all forms of pharmaceutically acceptable salts, prodrugs and metabolites thereof, in a controlled dosage form that is capable of maintaining plasma levels above about 10 micro g / ml for a period greater than 10.5 hours. These are useful in the treatment of pain and inflammation with a lower incidence of side effects.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4563597P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039628A2 true AR039628A2 (en) | 2005-03-02 |
Family
ID=21939053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (en) | 1997-05-05 | 1998-05-05 | PROCEDURE FOR THE TREATMENT OR PREVENTION OF PAIN AND PROCESSES AND INFLAMMATORY DISEASES, PHARMACEUTICAL COMPOSITION, PACK FOR USE IN THE MARKET IN SUCH PROCEDURE |
| ARP030101251A AR039628A2 (en) | 1997-05-05 | 2003-04-09 | MASSABLE FORMULATION OF CARPROPHENE, IMPLANT AND THERAPEUTIC COMPOSITION |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (en) | 1997-05-05 | 1998-05-05 | PROCEDURE FOR THE TREATMENT OR PREVENTION OF PAIN AND PROCESSES AND INFLAMMATORY DISEASES, PHARMACEUTICAL COMPOSITION, PACK FOR USE IN THE MARKET IN SUCH PROCEDURE |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0988034A1 (en) |
| JP (1) | JP2000513020A (en) |
| KR (2) | KR20010012300A (en) |
| CN (1) | CN1255059A (en) |
| AP (1) | AP9801234A0 (en) |
| AR (2) | AR011726A1 (en) |
| AU (1) | AU6932198A (en) |
| BG (1) | BG103852A (en) |
| BR (1) | BR9808720A (en) |
| CA (1) | CA2288759A1 (en) |
| DZ (1) | DZ2479A1 (en) |
| EA (1) | EA003696B1 (en) |
| GT (1) | GT199800063A (en) |
| HR (1) | HRP980244A2 (en) |
| HU (1) | HUP0001286A3 (en) |
| ID (1) | ID21311A (en) |
| IL (1) | IL132570A0 (en) |
| IS (1) | IS5220A (en) |
| MA (1) | MA26491A1 (en) |
| NO (1) | NO995389L (en) |
| NZ (1) | NZ500183A (en) |
| OA (1) | OA11213A (en) |
| PA (1) | PA8450601A1 (en) |
| PE (1) | PE72599A1 (en) |
| PL (1) | PL337003A1 (en) |
| SK (1) | SK148199A3 (en) |
| TN (1) | TNSN98059A1 (en) |
| TW (1) | TW590773B (en) |
| UY (1) | UY24989A1 (en) |
| WO (1) | WO1998050033A1 (en) |
| YU (1) | YU55899A (en) |
| ZA (1) | ZA983722B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| US6506785B2 (en) * | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| AU2003204888B2 (en) * | 1998-05-22 | 2005-07-28 | Pfizer Products Inc. | Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives |
| EP1123091A1 (en) * | 1998-10-23 | 2001-08-16 | Merck Frosst Canada & Co. | Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| EP1637137A3 (en) * | 1999-03-10 | 2006-07-05 | G.D. Searle LLC | Method and composition for administering a cyclooxygenase-2 inhibitor to animals |
| WO2001034204A1 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| JP2004521856A (en) * | 2000-05-15 | 2004-07-22 | メルク フロスト カナダ アンド カンパニー | Combination therapy using a COX-2 selective inhibitor and a thromboxane inhibitor and compositions therefor |
| CA2411960C (en) | 2000-06-13 | 2010-10-12 | Wyeth | Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| DE10032132A1 (en) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition |
| EP1307538B1 (en) | 2000-08-07 | 2009-01-07 | Vanderbilt University | Detection of cox-2 activity and anandamide metabolites |
| WO2003007875A2 (en) * | 2001-07-16 | 2003-01-30 | Hoegestaett Edward | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| DK1534305T3 (en) | 2003-05-07 | 2007-02-05 | Osteologix As | Treatment of cartilage / bone disorders with water-soluble strontium salts |
| CA2533101A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| US20080269310A1 (en) * | 2005-05-20 | 2008-10-30 | Adrian Paul Foster | Synergistic Combinations |
| DK2079456T3 (en) | 2007-04-04 | 2013-03-18 | Sigmoid Pharma Ltd | PHARMACEUTICAL CYCLOSPORINE COMPOSITIONS |
| EP2061587A1 (en) | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| BRPI1012196B1 (en) | 2009-05-18 | 2021-11-30 | Sublimity Therapeutics Limited | COMPOSITION INCLUDING OIL DROPS |
| EP2464341B1 (en) | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| ES2907285T3 (en) | 2014-03-06 | 2022-04-22 | Elanco Animal Health Incorporated | Grapiprant compositions and methods of use thereof |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| KR20170102223A (en) | 2014-11-07 | 2017-09-08 | 시그모이드 파마 리미티드 | Compositions comprising cyclosporin |
| CA2972996A1 (en) * | 2015-01-09 | 2016-07-14 | Jaguar Animal Health | Methods of treating diarrhea in companion animals |
| EP4125874A4 (en) * | 2020-03-25 | 2024-05-01 | SRI International | LIPOXYGENASE INHIBITORS |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (en) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | Pharmaceutical composition for preventing or treating keloid or hypertrophic scar comprising Benzbromarone |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
-
1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/en active
- 1998-04-30 TW TW087106689A patent/TW590773B/en not_active IP Right Cessation
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/en not_active Application Discontinuation
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/en not_active IP Right Cessation
- 1998-05-01 EA EA199900895A patent/EA003696B1/en not_active IP Right Cessation
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/en unknown
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/en not_active Application Discontinuation
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 IL IL13257098A patent/IL132570A0/en unknown
- 1998-05-01 PL PL98337003A patent/PL337003A1/en unknown
- 1998-05-01 JP JP10547869A patent/JP2000513020A/en active Pending
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Application Discontinuation
- 1998-05-01 CN CN98804845A patent/CN1255059A/en active Pending
- 1998-05-01 SK SK1481-99A patent/SK148199A3/en unknown
- 1998-05-01 ID IDP980651A patent/ID21311A/en unknown
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-01 YU YU55899A patent/YU55899A/en unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/en unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/en unknown
- 1998-05-04 UY UY24989A patent/UY24989A1/en not_active Application Discontinuation
- 1998-05-04 PE PE1998000335A patent/PE72599A1/en not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 MA MA25059A patent/MA26491A1/en unknown
- 1998-05-04 GT GT199800063A patent/GT199800063A/en unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/en not_active Application Discontinuation
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/en unknown
- 1998-05-05 AR ARP980102089A patent/AR011726A1/en unknown
-
1999
- 1999-10-19 IS IS5220A patent/IS5220A/en unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/en unknown
- 1999-11-04 NO NO995389A patent/NO995389L/en not_active Application Discontinuation
-
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039628A2 (en) | MASSABLE FORMULATION OF CARPROPHENE, IMPLANT AND THERAPEUTIC COMPOSITION | |
| AR013477A1 (en) | PROSTAGLANDINAS OF REPLACED TETRAHIDRO C16-20 AROMATICO USEFUL AS FP AGONISTS. | |
| DK0524587T3 (en) | Therapeutic compositions for intranasal administration containing Ketorolac R | |
| AR008377A1 (en) | A COMPOUND DERIVED FROM 3-AROYLBENCIL-PIRIDAZINONE, A PARTICULAR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES CONTAINING SUCH A COMPOUND | |
| RU97117350A (en) | INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT | |
| PA8426801A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RHINITIS. | |
| MY106552A (en) | Novel pyrido[2,3-f] [1,4]thiazepines and pyrido[3,2-b] [1,5] benzothiazepines. | |
| DE60003194D1 (en) | SEDATIVE HYPNOTIC COMPOSITIONS WITH CONTROLLED RELEASE AND RELATED PROCEDURE | |
| SE0104333D0 (en) | Therapeutic agents | |
| NO964216L (en) | Ester and carbamate derivatives of azolones which are powerful agents against Helicobacter | |
| CO5271694A1 (en) | BETA DI-REPLACED INHIBITORS OF METALOPROTEASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR APPLICATION | |
| SE9900190D0 (en) | New compounds | |
| PE20050139A1 (en) | COMPOUNDS DERIVED FROM HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS | |
| AR013538A1 (en) | NEW OSTEOBLAST SPECIFIC MYTHOGENES, METHODS FOR PREPARING THEM, AND DRUGS CONTAINING SUCH COMPOUNDS | |
| NO171363C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE OXYSALICYLAMINO DERIVATIVES | |
| IT1244696B (en) | QUINOLONIC DERIVATIVE FOR ANTIBACTERIAL AND MUCOLITIC ACTIVITY | |
| ES8104271A1 (en) | Novel antihypertensive agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |